Actinium Pharmaceuticals, Inc. (ATNM)

Net income growth under 50% of TRAW's 70.28%. Michael Burry would suspect deeper structural issues in generating bottom-line growth.

D&A growth of 3.11% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.

Negative yoy deferred tax while TRAW stands at 0.00%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.

Both cut yoy SBC, with TRAW at -5.73%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.

Well above TRAW's 14.88% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.

AP growth well above TRAW's 356.57%. Michael Burry would be concerned about potential late payments or short-term liquidity strain relative to competitor.

Both reduce yoy usage, with TRAW at -182.66%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.

Operating cash flow growth below 50% of TRAW's 28.87%. Michael Burry would see a serious shortfall in day-to-day cash profitability.

CapEx growth of 90.96% while TRAW is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.

No Data available this quarter, please select a different quarter.

We expand invests by 90.96% while TRAW is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.

We cut debt repayment yoy while TRAW is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.

No Data available this quarter, please select a different quarter.